Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Japan’s Premier Clinical CRO A2 Healthcare, an ITOCHU Subsidiary, Launches US Expansion

A2 Healthcare

A2 Healthcare, ITOCHU Corporation’s (ITOCY) leading subsidiary in healthcare headquartered in Tokyo, Japan, announced its US expansion. Leveraging regulatory strategy and clinical development expertise in Japan and Taiwan on a global scale, A2 Healthcare aims to transform the Japanese drug market, the third largest in the world. The company will support new drug development in Japan by expanding its partnerships with biotech and pharmaceutical companies based in the United States, the world leader in biopharmaceutical R&D. The United States accounts for around a third of the global market, according to the Pharmaceutical Research and Manufacturers Association (PhRMA). A2 Healthcare President and CEO Hitoshi Kamiya is confident that the Boston branch will help US companies navigate the Japanese market. “Pharmaceutical companies shy away from the Japanese market due to Japan’s strict pharmaceutical regulations, complex clinical trial-related procedures, and drug pricing system that differs from Europe and the United States. Hence, fewer new drugs enter the Japanese market, creating ‘drug loss.’ In 2020, 72 percent of drugs approved in Europe and the United States were not approved in Japan,” said Kamiya. “Unfortunately, this rate is on the rise. More than half of the domestically unapproved drugs in Japan are developed by biotech companies overseas. With the launch of the US office in Boston, A2 Healthcare is optimally positioned to change this narrative. We are offering a new mechanism to eliminate drug loss by encouraging companies to develop drugs in Japan at ease.” As a top CRO in Japan, A2 Healthcare has successfully supported new drug development, including a large number of sponsor-initiated clinical trials and investigator-initiated studies in various fields and diseases. A2 Healthcare’s advanced use of IT in its innovative clinical trials and high patient enrollment results in Japan were recognized with the “Best CRO/CDMO” prize from the Citeline Pharma Intelligence Awards Japan in October 2023. The Boston metropolitan area is an ideal networking environment as part of the world's largest biotech cluster with more than 1,000 biotech companies working on new drug development pipelines. A2 Healthcare will also offer its Pipeline Accelerator Program, a financing program for these companies. Hiroki Matsushima, head of A2 Healthcare’s Global Business Expansion in charge of the US Boston Office, stated, “Boston is the perfect location for launching global CRO services for new drug development in Japan, especially in supporting the development of drugs highly sought after by Japanese patients.” He added, “Japan is a country with a population of over 120 million people and an average lifespan of 84 years. In clinical trials, patient compliance is very high, while the drop-out rate is low. Sustained by a large patient pool for most target indications, Japan remains one of the most attractive and cost-effective places to implement global drug development plans. Additionally, Japan's low inflation over the past decades has helped keep costs down, unlike in most other countries.” A trusted partner for the global life science, medical and pharmaceutical industries, A2 Healthcare offers the most efficient regulatory pathway in Japan for new drug development and regulatory submissions to gain approval. Combining extensive clinical experience and 84 million patient data from 97,000 Japanese sites in the company’s own database, A2 Healthcare has recently achieved a 96 percent enrollment compliance rate within the agreed schedule, setting an impressive standard in the CRO industry. For more information about A2 Healthcare’s services and to request business meetings, contact the Boston Office at matsushima-h@a2healthcare.com or +1(857) 265-0605. ### About A2 Healthcare Corporation A2 Healthcare Corporation, an ITOCHU company, is a premier clinical contract research organization (CRO) founded in 2003 to enhance the quality of lives. Specializing in global clinical trial and research services, we support the development of new drug treatments across wide-ranging therapeutic areas and modalities. A2 Healthcare operates in the United States, Japan and Taiwan, leading the industry by providing best-in-class quality and deliverables through its clinical operations. For more information, visit www.a2healthcare.com/en. Media Contact: A2 Healthcare US Boston Office Hiroki MATSUSHIMA matsushima-h@a2healthcare.com +1(857) 265-0605 A2 Healthcare Japan PR: marke@a2healthcare.com Investor Relations: watanabe-se@a2healthcare.com Contact Details A2 Healthcare US Boston Office Hiroki MATSUSHIMA +1 857-265-0605 matsushima-h@a2healthcare.com

April 17, 2024 08:04 AM Eastern Daylight Time

Clarified Precision Medicine Raises $1.2 Million in Seed Funding and Appoints Health Tech Leader Rajni Natesan, MD, MBA as CEO

Clarified Precision Medicine

Clarified Precision Medicine, the only company that provides oncologists with prioritized therapy options via a combination of algorithmic testing and physician oversight, announced that it closed on its seed round of $1.2 million led by Avestria Ventures, with participation from Joyance Partners, both early-stage funds focused on improving health. The company also named Rajni Natesan, MD, MBA as its Chief Executive Officer. Dr. Natesan is an experienced executive and medical doctor with an extensive background scaling startups at the intersection of healthcare and technology, with a focus on artificial intelligence and machine learning. “Clarified Precision Medicine is offering the right technology at the right time,” Dr. Natesan said. “I’m excited to guide Clarified through this period of commercialization and growth as we follow through on our mission to provide any patient, anywhere, with cutting-edge, guidelines-based access to precision medicine.” Founded in 2021 by Dr. Lincoln Nadauld, MD, PhD, Lisa Alderson, MBA, Howard McLeod, PharmD, and Jody Simon, PharmD, Clarified Precision Medicine uses an algorithm to analyze NGS lab results and then works with oncologists to interpret genomic test results to recommend the best targeted treatment. I n the United States, there are 18 million patients with a history of cancer and 1.9 million new cancer diagnoses each year. Patients who receive precision therapies have survival rates that are three times greater than those who do not. However, 75 percent of doctors say they need help interpreting genomic tests—which leads to more effective utilization of these powerful 21-century tools. Clarified’s combination of advanced technology and physician oversight provides oncologists at community cancer centers with the precision treatment knowledge and expertise usually reserved for leading research institutions. “Dr. Natesan is the perfect leader to help us scale Clarified Precision Medicine to ensure that oncology practices across the country have access to expert guidance to deliver improved outcomes,” said Clarified Precision Medicine Co-founder Lisa Alderson. “She has the right combination of business acumen and clinical expertise to drive adoption and engage with key stakeholders to make world-class precision medicine expertise accessible to every cancer patient and every oncology practice. We’re excited to support Dr. Natesan as she leads us into the next chapter of growth.” With deep C-suite expertise in finance, strategy, operations and clinical functions across medical devices and health tech, Dr. Natesan has led companies across all phases of their product and organizational life cycles, from conceptual design to FDA trials, commercialization, IP and M&A preparation. Dr. Natesan began her career as one of the first physicians on Wall Street, leading health care mergers, acquisitions and financing deals for pharma, biotech and med device clients as an investment banker in Lehman Brothers’ health care group and as a health care strategy consultant in a boutique practice. Most recently, Dr. Natesan served as Chief Strategy and Medical Officer at Braid Health, a venture-backed, disruptive digital health infrastructure company. Clarified Precision Medicine is already supporting numerous U.S. oncology practices and testing labs and offers flexible payment options, including direct insurance billing in some cases. More information on Clarified Precision Medicine solutions is available from the Clarified Precision Medicine Business Development team. About Clarified Precision Medicine Clarified Precision Medicine is the first scalable molecular tumor board with a combination of ML-based platform plus medical group, offering expert clinical somatic and pharmacogenomics consultations through its ClarifiedSelect™ and OncoGuardian™ solutions. Clarified accelerates the delivery of guidelines-based genomic insights to patients and providers by bringing together nationally recognized experts in medical oncology, oncology pharmacy, data integration, and molecular pathology who have over 100 years of collective experience in the application of precision oncology. For more information, visit: www.clarifiedprecisionmedicine.com Contact Details For Clarified Precision Medicine info@clarifiedmedicine.com Company Website https://clarifiedprecisionmedicine.com/

April 16, 2024 10:09 AM Eastern Daylight Time

PathAI Partners with Google Cloud to Transform Drug Discovery and Precision Medicine Through AI-Powered Pathology

PathAI

PathAI, a global leader in AI-powered pathology, today announced a strategic partnership with Google Cloud at Bio-IT World Conference & Expo to help biopharma companies and anatomic pathology (AP) labs accelerate the adoption of AI and digital pathology. PathAI’s AISight 1 Intelligent Image Management System (IMS) is an AI-native IMS that seamlessly blends PathAI and third-party algorithms into a single laboratory workflow and image analysis platform, providing researchers and pathologists direct access to powerful biomarker quantification tools that have the potential to increase lab operational efficiency and aid in disease staging and scoring. PathAI will leverage Google Cloud’s infrastructure to bring AISight to more biopharma companies and AP labs worldwide, enabling faster deployments of novel AI models for a variety of clinical and research needs. "Bio-IT World is where pioneers convene to address the industry's most significant challenges, including how to leverage massive scale data from biological and clinical studies to accelerate the discovery and development of transformative new therapies for patients. PathAI partners across the drug development paradigm, firstly with biopharma by enabling the development of new insights and diagnostics and supporting global clinical trials through PathAI’s AISight Clinical Trials platform, trial-ready algorithms, and Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) compliant laboratory; and also with AP labs ensuring scaled access to algorithms through AISight," said Dr. Andy Beck, CEO and co-founder of PathAI. "Our partnership with Google Cloud helps us transform our capabilities to accelerate adoption of these powerful tools and ultimately reshape how disease is understood and treated.” The partnership will involve the integration of PathAI’s AISight solution with Google Cloud's infrastructure and AI capabilities, providing: Accelerated adoption of precision medicine solutions: Google Cloud's infrastructure enables rapid scaling of AISight's digital pathology IMS and algorithmic capabilities globally, aiding digital pathology laboratory operations and researchers in processing petabytes worth of data for large-scale biomarker discovery and clinical studies, ultimately bringing advancements to patients more quickly. Customized solutions and tailored AI models: The latest Google Cloud AI tools within the AISight platform provide the ability to quickly develop customized solutions and deploy novel AI models tailored to specific research needs. "We understand the urgent need within the biopharmaceutical industry for secure, scalable solutions in AI-driven drug discovery, laboratory operations, and biomarker quantification,” said Ryan Terry, managing director, Healthcare and Life Sciences, Google Cloud. "We're incredibly excited to partner with PathAI to create a new wave of solutions that leverage precision medicine to help solve the industry’s most significant challenges." 1 AISight is For Research Use Only. Not for use in diagnostic procedures. About PathAI PathAI is dedicated to improving patient outcomes through its groundbreaking AI-powered pathology platform. Our solutions provide invaluable insights for biopharmaceutical companies, researchers, and laboratories, ultimately enabling precision pathology and the vision of more effective treatments. Learn more at www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

April 16, 2024 09:00 AM Eastern Daylight Time

Unicorn Hailo Closes $120 Million Funding Round, Debuts Powerful Hailo-10 AI Accelerator Bringing GenAI To Edge Devices

OurCrowd

By Matthew Kalman Hailo, the pioneering chipmaker of edge artificial intelligence (AI) processors, announced the successful extension of its series C fundraising round with an additional investment of $120 million, bringing its valuation to more than $1 billion, Bloomberg reported. The successful close is “the latest sign of investor enthusiasm for startups that can help address a global chip shortage and fuel the development of generative AI,” Bloomberg reported. The company also announced the introduction of its innovative Hailo-10 high-performance generative AI (GenAI) accelerators that usher in an era where users can own and run GenAI applications locally – including on many edge devices – without registering to cloud-based GenAI services. “Hailo’s chips execute AI tasks with lower memory usage and power consumption than a typical processor, making them a strong candidate for compact, offline and battery-powered devices such as cars, smart cameras and robotics,” said TechCrunch. While the funding round has officially closed, investors can still participate in this raise for a limited period via an exclusive allocation available through OurCrowd, the online investment platform. “OurCrowd first invested in Hailo when it was valued at about $30 million. Now it’s a unicorn,” said Jon Medved, OurCrowd’s Founder and CEO. “We are excited and delighted to be able to offer investors the opportunity to participate in the development of impressive startups like this.” The current round brings Hailo’s total funding to more than $340 million. “The closing of our new funding round enables us to leverage all the exciting opportunities in our pipeline, while setting the stage for our long-term future growth,” said Orr Danon Hailo’s CEO and Co-Founder. “Together with the introduction of our Hailo-10 GenAI accelerator, it strategically positions us to bring classic and generative AI to edge devices in ways that will significantly expand the reach and impact of this remarkable new technology.” “We designed Hailo-10 to seamlessly integrate GenAI capabilities into users’ daily lives, freeing users from cloud network constraints. This empowers them to utilize chatbots, copilots, and other emerging content generation tools with unparalleled flexibility and immediacy, enhancing productivity and enriching lives,” Danon said. GenAI At The Edge The new Hailo-10 GenAI accelerator enables a whole spectrum of applications that maintain Hailo’s leadership in both performance-to-cost ratio and performance-to-power consumption ratio. Hailo-10 leverages the same comprehensive software suite used across the Hailo-8 AI accelerators and the Hailo-15 AI vision processors, enabling seamless integration of AI capabilities across multiple edge devices and platforms. Enabling GenAI at the edge ensures continuous access to GenAI services, regardless of network connectivity; obviates network latency concerns, which can otherwise impact GenAI performance; promotes privacy by keeping personal information anonymized and enhances sustainability by reducing reliance on the substantial processing power of cloud data centers. By unlocking the power of GenAI on edge devices, such as personal computers, smart vehicles and commercial robots, Hailo-10 allows users to completely own their GenAI experiences, making them an integral part of their daily routine. Hailo accomplishes this immersive GenAI experience through a Hailo-10 architecture that supports maximum GenAI performance with minimum required power. “As GenAI on the edge becomes immersive, the focus turns to handling large LLMs in the smallest possible power envelope — essentially less than five watts,” Danon said. Since its founding in Israel in 2017, Hailo has become a leading global supplier of intelligent AI chips that serves more than 300 customers around the world. The company has offices in the United States, Europe, Japan, South Korea, China and Taiwan. “Whether users employ GenAI to automate real-time translation or summarization services, generate software code, or images and videos from text prompts, Hailo-10 lets them do it directly on their PCs or other edge systems, without straining the CPU or draining the battery,” Danon said. Top Class Performance Hailo’s specialized AI processors enable data center-class performance on edge devices. Hailo’s processors are the product of a rethinking of traditional computer architecture, enabling smart devices to perform sophisticated deep learning tasks such as object detection and segmentation in real-time, with minimal power consumption, size and cost. The processors are designed to fit into a multitude of smart machines and devices, impacting a variety of sectors including compute, automotive, security, industry 4.0, and retail. Early applications of Hailo-10 GenAI accelerators will be targeting PCs and automotive infotainment systems, empowering current and future CPUs that cannot by themselves power the chatbots, copilots, personal assistants and speech-operated operating systems that have become standard today. Hailo will begin shipping samples of the Hailo-10 GenAI accelerator in Q2 of 2024. Among popular GenAI platforms, Hailo-10 can run Llama2-7B with up to 10 tokens per second (TPS) at under 5W of power. In processing Stable Diffusion 2.1, a popular model that produces images from text prompts, Hailo-10 is rated at under 5 seconds per image in the same ultra-low power envelope. Hailo-10 is capable of up to 40 TOPS (tera operations per second), a new performance standard for edge AI accelerators. Hailo-10 is faster and more energy efficient than integrated neural processing unit (NPU) solutions and delivers at least 2X more performance at half the power of Intel’s Core Ultra NPU, according to recently published benchmarks. Hailo will be present at the Embedded World exhibition in Nuremberg, April 9-11, Booth 126, Hall 1, and at the ISC West exhibition in Las Vegas, April 10-12, Booth #31065. For more information about investing in Hailo via the OurCrowd platform, click HERE. Featured photo courtesy of OurCrowd. OurCrowd was started in 2013, driven by the idea that the business of building startups grows bigger and better when the global ‘crowd’ gains access to VC-level investment opportunities.Today, OurCrowd is a global venture and alternative investing platform that empowers institutions and individuals to invest and engage in emerging companies. OurCrowd vets and selects companies, invests its capital, and provides its global network with unparalleled access to co-invest and contribute connections, talent and deal flow. OurCrowd builds value for its portfolio companies throughout their lifecycles, providing mentorship, recruiting industry advisors, navigating follow-on rounds and creating growth opportunities through its network of multinational partnerships. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Lisa Graston lisa.graston@ourcrowd.com Company Website http://www.ourcrowd.com

April 16, 2024 08:45 AM Eastern Daylight Time

Video Image

DentalPlans.com Making Braces Affordable, Less Stressful For American Parents

DentalPlans.com

By Faith Ashmore, Benzinga Braces are often a coming-of-age experience for many young children – and potentially simultaneously a financial burden for their parents. In today’s market, the average cost of metal braces, which are the cheapest option available, is $3,000 to $7,000. However, these ranges can go up to around $10,000 if there is more extensive work needed or a preference for ceramic or lingual braces. Summertime is often the preferred time for children and parents alike to start the braces journey. Without school, appointments are much easier to make without stressing that children are missing valuable classroom time. Overall, summertime is marked by fewer worries, fewer obligations and more time to adjust to the new braces. With summer right around the corner, many parents are starting to balance budgets to ensure their children get the oral care they need. While many may assume that dental insurance will cover the cost, this is rarely the reality. The majority of dental insurance plans have an annual maximum spending limit of $1,000-$2,000 and may even have a lifetime limit on coverage for orthodontics. At best, a portion of the overall cost will be covered, but check your plan details since coverage varies. Dental Savings Plans As An Alternative That’s where dental savings plans can provide relief for millions of American families, as a trusted and affordable alternative to dental insurance. A dental savings plan is a subscription-based program that provides plan members with discounts on dental services from participating dentists and orthodontists. Unlike dental insurance, which typically involves monthly premiums, copayments, deductibles and coverage limits, dental savings plans work on a fee-for-service basis. Dental savings plans typically provide around 20% off braces, which can be more than $1,000 in savings per person. For all other procedures, dental savings plans typically result in savings of 10%-60% and there is no limit to how much you can use these plans, unlike dental insurance which has finite yearly caps. DentalPlans.com is celebrating its 25th anniversary and has prided itself on helping over a million customers save on their dental care since its launch in 1999. The company started as an online marketplace for dental savings plans but has now expanded to offer both dental savings plans and insurance. In 2023, the company launched an online plan finder, which asks users a few quick questions and then provides them with a personalized plan recommendation in minutes. With so many different types of plans available, the online plan finder can be a lifesaver for parents who want the best care for their children. There is also a search feature where they can look for dentists, orthodontists, and see which plans are accepted by those practitioners. Instead of being overwhelmed by the plethora of plans available online or feeling deterred and not knowing where to begin planning, DentalPlans.com makes it simple and hassle-free. Featured photo by Arribalko on Shutterstock DentalPlans.com, founded in 1999, is a leading online marketplace for dental savings plans in the U.S., helping more than a million people to affordably access quality healthcare services. Our mission is to empower consumers with the tools, information, and services that they need to live happier, healthier lives. Discount Health Program consumer & provider surveys indicate average savings of 50%. Savings may vary by provider, location, and plan. Sample savings are based on zip code 43614, actual costs and savings may vary service and geographical area. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Matthew Wong matthew.wong@wpromote.com Company Website https://www.dentalplans.com/

April 16, 2024 08:30 AM Eastern Daylight Time

Image

Isospec Analytics raises $1.9m as it introduces breakthrough technology to rapidly identify unknown molecules at scale

Isospec Analytics

When developing new drugs, nutitional products, or pesticides, it’s critical that unknown molecules are identified correctly. But accurate identification is a lengthy process and all too often unsuccessful, leading to failed regulatory processes, or worse, consumer health being put in danger. Today, Isospec Analytics has raised $1.9M to commercialize new technologies for molecular analysis that rapidly identify unknown molecules in minutes, helping pharmaceuticals, nutrition and agritech companies develop safer products and enabling researchers to discover new biomarkers. Isospec’s $1.9M pre-seed round is led by Founderful (formerly Wingman Ventures), with additional participation from specialized investors Tiny.vc, another.vc and Venture Kick. Isospec was founded in 2022 by Ahmed Ben Faleh, Stephan Warnke, and Thomas Rizzo, who partnered together to explore how they could redefine the process of molecular analysis to access new biological information and enable breakthroughs in diagnostics, therapeutics, and nutrition. Based on over 20 years of research, the founders combined technologies from multiple disciplines – analytical chemistry, photonics, and cryogenic materials initially designed for space applications – to build a tool that can generate a new data dimension about molecular structures. This allows for the identification of molecules which were, until now, unknown. Today, identifying an unknown molecule is primarily based on mass analysis, which does not provide sufficient information. Identifying a by-product or an impurity requires the combination of high sensitivity to detect trace amounts in a sample, coupled with the ability to generate data that can definitively identify the structure of a molecule. Existing tools lack either one or both of these capabilities. “Unfortunately, mass alone does not uniquely determine the structure of a molecule. Several different molecules can have exactly the same mass, called isomers, but totally different properties. For example, one isomer might be toxic, while another may be a life-saving therapeutic,” said Thomas Rizzo, Professor of Chemistry at EPFL. Definitive molecular identification currently requires the combination of several techniques and a lengthy process including purification and multiple syntheses. Companies developing new products are thus faced with a dilemma: either spend months identifying unknowns and delay their go-to-market, or move forward based on guesses and risk failing regulatory requirements and endanger consumer health. In comparison, Isospec’s technology generates unique, information-rich metrics that allow for the rapid identification of unknown molecules in minutes instead of months, bringing unprecedented scalability to molecular identification. “By adding infrared analysis directly inside a mass spectrometer, we have a valuable new dimension by which to identify molecules,” adds Professor Thomas Rizzo. Originating from the Laboratory of Molecular Physical Chemistry (LCPM) at EPFL, Isospec’s breakthrough technology is already being used in the analysis of sugars and metabolites within the food and agritech industry to carry out quality control and support product R&D. However, the team believes the real potential of their technology is in the discovery of new biomarkers for therapeutics development and diagnostics. “In a human blood sample, there are 15,000 small biological molecules that can give precise information about a person’s health at any given time. However, less than 5% of these molecules can be identified. The ability to rapidly identify new molecules means we can now leverage the 95% unknown molecular space to develop treatments to the deadliest diseases,” said co-founder and CEO Dr. Ahmed Ben Faleh. These combined use cases were compelling for Isospec’s investors. “Isospec’s value proposition, which offers early access to its cutting-edge research in biomolecular analysis as a service, convinced us of the potential of the technology and the team,” explains Alex Stöckl, partner at Founderful and board member of Isospec. “Isospec is one of the first 8 companies in which we have invested with our second fund, which aims to reach $120M.” The team is currently working on the scalability of their platform, introducing automation at every step and implementing machine learning tools for data analysis and insight generation. “This round allows us to build a software team composed of experts in data engineering,” said Dr Ahmed Ben Faleh. Against the highly competitive backdrop of the sugar and metabolite analytical markets, Isospec is setting its sights on becoming the leading provider of molecular analysis solutions and biomarker discovery technology. About Isospec Isospec Analytics is an EPFL spin-off based in Lausanne – Switzerland, whose mission is to implement technology to discover new disease biomarkers, accelerate the development of therapeutics and transform the future of clinical nutrition. For more information please visit IsoSpec Analytics About Founderful Founderful is Switzerland’s leading pre-seed fund. We give every founder our deepest understanding and highest levels of support, and together, we’re building the future of the Swiss startup ecosystem. Contact Details isospec Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.isospecanalytics.com/

April 16, 2024 08:00 AM Eastern Daylight Time

Image

News Release

NuggMD to Again Offer Cannabis Support Line, the Too-High Hotline, on 4/20

NuggMD

NuggMD, the nation's leading medical marijuana telemedicine platform, is once again helping accidental cannabis over-indulgers find support this 4/20 with its Too-High Hotline. The hotline (323-518-2728), first established last April, is a resource for consumers who, for whatever reason—cough, cough—want a friendly voice who will converse with them, calm them down, or just listen. States have seen an explosion in much-needed harm- and anxiety-reduction measures, thanks to the reduced stigma around cannabis use. Still, many Americans resist seeking help for highly emotional psychedelic experiences because cannabis is still illegal at the federal level. This results in unguided use by consumers who are unprepared to handle unusual mental effects. It is why emergency-room visits for the overconsumption of cannabis usually spike on April 20. “To be clear: Yes, this is a real service. Anyone who consumes, or consumes too much, this April 20 can call us and talk to us about whatever they want to. No judgments,” said Alex Milligan, co-founder and CMO of NuggMD. He continued: “There is also a serious side to the 4/20 holiday that I hope gets more attention this year. The cannabis movement acknowledges the need for harm-reduction measures as the substance continues to gain mainstream acceptance. Use of the plant affects different people in different ways, and the truth is that some of those effects are negative or unpleasant. So, beyond setting up the Too-High Hotline every April, we are committed to consumer empowerment and education every day throughout the year.” NuggMD’s Too-High Hotline is available to everyone in the United States this 4/20 to offer support during or after their cannabis experience. NuggMD is also educating patients about harm reduction and support options through a dedicated landing page, nationwide email notifications to its network of more than a million patients, and additional ongoing campaigns focused on harm reduction and safe consumption. To learn more about NuggMD’s Too High Hotline, please visit https://www.nuggmd.com/support. About NuggMD NuggMD is the nation's leading medical marijuana technology platform, serving patients in Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, Washington, and West Virginia. They've connected over 1,300,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit https://www.nuggmd.com. Contact Details Andrew Graham +1 646-385-0189 andrew.g@getnugg.com Company Website http://www.nuggmd.com

April 15, 2024 04:41 PM Eastern Daylight Time

CoverSelf appoints Ashish Singh, Advisory Partner at Bain & Company, as Board Director

CoverSelf

CoverSelf, a unified platform for healthcare claims and payment integrity, is today announcing the appointment of Ashish Singh, Advisory Partner at Bain & Company, as Board Director. This development comes on the heels of the company’s recent close of a $8.2 million seed round. Ashish is a well-known and deeply respected Bain & Company leader. He led Bain’s global Healthcare and Life Sciences (HLS) practice from 2012 to 2018 and served two terms on Bain’s global Board of Directors in the same time period. Ashish also founded Bain & Company’s India office and was at its helm as Managing Director (2005-2011) and Chairman (2011-2014). Over the years, he also co-founded Bain’s Enterprise Software, Media & Entertainment, Pharmaceutical and Payer practices. Ashish’s expertise lies in corporate and BU strategies, market entry strategies, operational improvement, organisational effectiveness, M&A, healthcare IT, and large-scale corporate transformation programs. “We are thrilled to welcome Ashish onboard as our Board Director. He is a veteran in this space and brings invaluable experience in formulating overall strategy and US GTM strategy, as well as in-depth knowledge of the US healthcare system and health plans. Not to mention, his broad network of relationships across the industry will benefit us in the long term,” said Rajasekhar Maddireddy, Co-founder of CoverSelf. “We’ve been busy since our funding announcement. We are already live as the secondary editor in three health plans, with an expansion to another four over the next six months in the works. We are in full-scale implementation with a top 10 health plan, and executing a PoC with a Top 5 health plan. These are showing remarkable results, wherein the platform is processing 25 times more claims in the same time window than was done earlier. We will soon start initial moves into markets adjacent to the payment integrity (PI) space via collaboration with a focused set of partners to bring broader integrated solutions to our clients.” CoverSelf was founded in 2021 by US healthcare domain experts Rajasekhar Maddireddy and Raghavendra Pawar to tackle the ever-increasing claims inaccuracies and waste. The company aims to democratize the healthcare claims and payment integrity industry by creating a first-of-its-kind, fully open and transparent solution that empowers payment integrity teams in health insurance companies (payers) to transparently resolve health claims with hospitals and medical practices (providers). CoverSelf’s purpose-built platform utilizes multiple approaches, including the smart use of GenAI, to reduce waste while identifying new savings opportunities. The platform empowers payers to adapt to claims and payment inaccuracies by enabling them to configure their policies and logic in simple English-like language or use simple policy-specific templates, overcoming the fear of losing IP and fostering innovation and new concept releases without technical dependencies. “According to recent reports, the $9 billion PI industry has grown at around 7% CAGR in recent years. This just shows the inherent complexity of the billing processes. The truth is, over the years, there has been a perceptible negative impact on providers' experience with payments, and trust in payers has taken a significant hit. This has resulted in ballooning waste and improper payments. Given this scenario, I’m glad to lend a helping hand to CoverSelf’s mission,” said Ashish Singh, Board Director of CoverSelf. “I will work closely with the co-founders and top management to increase Coverself's visibility amongst healthcare payers and technology partners and also bring my expertise to assist them in corporate and market strategy. What we are doing in CoverSelf is not just building a product that is looking to solve a few pain points; we are on a once-in-a-lifetime mission to truly democratize healthcare claims and payment integrity and restore faith in the US’s healthcare ecosystem!” About CoverSelf CoverSelf is a generational leap forward in healthcare claims and Payment Integrity architecture, built from the ground up for healthcare-specific use by passionate domain experts and strong technology professionals with decades of experience in addressing the pain points faced by Providers and Payers when dealing with the latest technological advancements. Founded in 2021, CoverSelf’s Payment Integrity Platform engages modern technologies to address payment leakage & claims inaccuracies while remaining transparent & accessible to Payers. The platform empowers payers to prevent and adapt to the ever-evolving claims & payment inaccuracies. We also help you reduce complexity and administrative costs with our unified healthcare dedicated platform. Contact Details CoverSelf Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.coverself.com/

April 15, 2024 09:59 AM Pacific Daylight Time

Image

Comtex Launches Omnia: A Cutting-Edge News API Platform leveraging NLP and AI

Comtex

Comtex News Network, Inc (Comtex), a leading provider of news aggregation and distribution services to top firms in financial services, news publishing, syndication, and analytics, proudly announces the launch of its innovative API platform, Omnia. Omnia is a state-of-the-art API platform designed to revolutionize the way businesses access and utilize news content. Omnia empowers users with instant access to real-time streaming news, AI-generated article summaries, enhanced tagging and categorization based on NLP, advanced filtering, and access to an extensive catalog of curated news sources. Key Features of Omnia Include: Real-time Streaming News: Omnia provides real-time streaming news via websockets push and REST API for seamless integration into existing systems. Enhanced Tagging and Categorization: Leveraging AI and proprietary NLP-based algorithms, Omnia offers enhanced tagging and categorization of content, including press releases, earnings releases, product categories, and more. AI-Generated Article Summaries: Omnia utilizes AI to generate concise and searchable article summaries, enabling users to quickly grasp an article before reading it. Advanced Filtering: Omnia's advanced filtering capabilities allow users to customize their news feeds based on specific criteria, ensuring they receive only the most relevant content. Access to an extensive collection of curated, high-quality sources used by top companies in financial services, analytics, research and a broad range of industries. Omnia is designed for rapid integration and serves a variety of use cases, including training of LLMs, financial platforms, asset management, trading, academic research, legal research, market research, and much more. Commenting on the launch, Comtex CEO Kan Devnani said, "We are pleased to bring a flexible, state-of-the-art news platform with access to curated, premium news sources to market. Omnia is an extendable platform, combining AI with our rich experience applying NLP to news content. This will allow clients to derive more intelligence and insights from the news content we offer and help clients curate and identify the content most relevant to them. Comtex will use Omnia to deliver evolving analytics and insight to its users." Access to Omnia can be trialed by visiting https://www.comtex.com/api. Comtex encourages users to explore its features and capabilities. To learn more about Omnia and request a demo, please contact sales@comtex.com or visit https://www.comtex.com/api. About Comtex News Network, Inc (Comtex): Comtex News Network Inc (Comtex) is a leading provider of news aggregation services to top firms in financial services, news publishing, syndication, and analytics. With a wealth of experience and expertise, Comtex delivers comprehensive news solutions that empower businesses to make informed decisions and stay ahead of the competition. Comtex also offers syndication services to content providers and platforms to generate traffic to online content. Contact Details Comtex News Network Media Relations sales@comtex.com

April 12, 2024 02:01 PM Eastern Daylight Time

1 ... 40 41 42 43 44 ... 308